MSC Promotes the Secretion of Exosomal miR-34a-5p and Improve Intestinal Barrier Function Through METTL3-Mediated

Yi-Jun Li1, Qing-Wen Xu1, Cong-Hui Xu1

  • 1Department of Gastrointestinal Surgery, Second Affiliated Hospital of Kunming Medical University, No.374, Dianmian Road, Kunming, 650101, Yunnan Province, People's Republic of China.

Insights

Mesenchymal stem cells (MSCs) protect against intestinal ischemia/reperfusion injury (IIRI) by secreting exosomal miR-34a-5p. This microRNA

Area of Science:

  • Gastroenterology
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Intestinal ischemia/reperfusion injury (IIRI) presents a significant clinical challenge with high mortality.
  • Mesenchymal stem cell (MSC) therapy shows promise, but the mechanisms of MSC-derived exosomes in IIRI are not fully understood.
  • Exosomal microRNAs (miRNAs) are crucial mediators, yet their role in MSC-based IIRI treatment requires investigation.

Purpose of the Study:

  • To investigate the function and regulatory mechanism of MSC-derived exosomal miRNAs in intestinal ischemia/reperfusion injury (IIRI).
  • To elucidate the role of miR-34a-5p and its regulatory pathway involving METTL3/IGF2BP3-mediated m6A modification in MSC-treated IIRI.

Main Methods:

  • Established in vitro and in vivo models of intestinal ischemia/reperfusion injury (IIRI).
  • Characterized mesenchymal stem cells (MSCs) and their derived exosomes using immunofluorescence, flow cytometry, TEM, and western blot.
  • Assessed cell viability, apoptosis, and intestinal integrity using CCK-8, TUNEL, and TER assays; analyzed molecular mechanisms via qRT-PCR, western blot, MeRIP-qPCR, RNA pull-down, and RIP assays.

Main Results:

  • MSC-derived exosomal miR-34a-5p significantly alleviated oxygen-glucose deprivation/reperfusion (OGD/R)-induced injury in vitro and in vivo.
  • MSCs ameliorated IIRI by modulating the METTL3/IGF2BP3 pathway, which mediates m6A modification of pre-miR-34A.
  • MSC treatment promoted the secretion of exosomal miR-34a-5p, enhancing intestinal barrier function.

Conclusions:

  • MSC-derived exosomal miR-34a-5p is a key therapeutic factor in mitigating intestinal ischemia/reperfusion injury.
  • The METTL3/IGF2BP3-mediated m6A modification of pre-miR-34a is a critical regulatory mechanism for exosome secretion and therapeutic efficacy.
  • This study highlights a novel therapeutic strategy utilizing MSC-derived exosomes for treating IIRI.